Motion sickness
diseaseOn this page
Also known as travel sickness
Summary
Motion sickness (MONDO:0008015) is a disease and 34 clinical trials. Top therapeutic interventions include scopolamine, ibuprofen, and sufentanil. A subtype of inner ear disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 34
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | motion sickness |
| Mondo ID | MONDO:0008015 |
| MeSH | D009041 |
| OMIM | 158280 |
| DOID | DOID:2951 |
| ICD-10-CM | T75.3 |
| ICD-11 | 1078108554 |
| UMLS | C0026603 |
| MedGen | 44503 |
| Is cancer (heuristic) | no |
Also known as: motion sickness · travel sickness
Disease family
This is a subtype of inner ear disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › motion sickness
Related subtypes (14): bilateral hyperactive labyrinth, labyrinthine bilateral reactive loss, labyrinthitis, labyrinthine unilateral reactive loss, unilateral hyperactive labyrinth, vestibular disorder, cochlear disorder, bilateral hypoactive labyrinth, unilateral hypoactive labyrinth, otosclerosis, X-linked mixed hearing loss with perilymphatic gusher, autoimmune inner ear disease, enlarged vestibular aqueduct syndrome, inner ear neoplasm
Subtypes (1): space motion sickness
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Scopolamine | Approved (phase 4) |
| Tradipitant | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Meclizine, Promethazine.
Clinical trials & evidence
Clinical trials
Clinical trials: 34.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE3 | 9 |
| PHASE2 | 4 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03755596 | PHASE4 | COMPLETED | Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness |
| NCT06232785 | PHASE4 | COMPLETED | Gynecologic Endoscopic Surgery of Female Motion Sickness Patients |
| NCT06587386 | PHASE4 | COMPLETED | The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function |
| NCT06138613 | PHASE3 | ACTIVE_NOT_RECRUITING | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| NCT02155309 | PHASE2/PHASE3 | TERMINATED | Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray |
| NCT03986905 | PHASE3 | COMPLETED | The Prevention and Treatment of Nausea Associated With Motion Sickness |
| NCT03988530 | PHASE3 | COMPLETED | Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects |
| NCT04184115 | PHASE3 | COMPLETED | Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness |
| NCT04219982 | PHASE2/PHASE3 | TERMINATED | DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness |
| NCT04272255 | PHASE3 | UNKNOWN | Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness |
| NCT04327661 | PHASE3 | COMPLETED | Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness |
| NCT04947423 | PHASE3 | COMPLETED | Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion |
| NCT05548270 | PHASE3 | COMPLETED | Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion |
| NCT05903924 | PHASE3 | COMPLETED | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| NCT05886660 | PHASE2 | RECRUITING | Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance |
| NCT00374478 | PHASE2 | COMPLETED | Effects of Transdermal Scopolamine on Occupational Performance |
| NCT02241629 | PHASE2 | COMPLETED | Levo Phencynonate Hydrochloride for the Prevention of Seasickness |
| NCT03772340 | PHASE2 | COMPLETED | Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness |
| NCT02839135 | PHASE1 | COMPLETED | A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. |
| NCT04999449 | PHASE1 | COMPLETED | Nebulizer Delivery of Intranasal Scopolamine |
| NCT05622344 | Not specified | RECRUITING | StableEyes With Active Neurofeedback |
| NCT06106256 | Not specified | ACTIVE_NOT_RECRUITING | Three-Axis Wearable Adaptive Vestibular Stimulator |
| NCT06892340 | Not specified | RECRUITING | Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation |
| NCT07297862 | Not specified | ENROLLING_BY_INVITATION | Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients |
| NCT02986555 | Not specified | UNKNOWN | Research on Quantification of VR(Virtual Reality) Related Stress and Relaxation |
| NCT04196933 | Not specified | WITHDRAWN | Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma |
| NCT04331561 | Not specified | WITHDRAWN | Sensory Training for Orientation and Balance |
| NCT04420949 | Not specified | COMPLETED | Sensory Training for Visual Motion Sickness |
| NCT05004818 | Not specified | COMPLETED | Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness |
| NCT05611814 | Not specified | COMPLETED | Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms |
| NCT05628220 | Not specified | UNKNOWN | Motion Sickness Desensitization Using VR |
| NCT06056622 | Not specified | COMPLETED | Motion Sickness Rehabilitation for Virtual Reality |
| NCT06128707 | Not specified | COMPLETED | Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study |
| NCT06354309 | Not specified | COMPLETED | Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SCOPOLAMINE | 4 | 6 |
| IBUPROFEN | 4 | 1 |
| SUFENTANIL | 4 | 1 |
| TRADIPITANT | 3 | 4 |
| CHEMBL1187846 | 0 | 5 |
| CHEMBL3084722 | 0 | 5 |
Related Atlas pages
- Drugs: Scopolamine, Ibuprofen, Sufentanil, Tradipitant